Explorer

India Engages With Domestic Pharma Exporters Amid US Tariff Concerns

The United States is a key market for India’s pharmaceutical exports, with India supplying around 40 per cent of all generic drugs used in the US

The Commerce Ministry is in active talks with Indian pharmaceutical exporters amid growing concerns over possible US tariffs on the sector, which was exempted in the first tranche of reciprocal tariffs by US President Donald Trump. The discussions between the government and pharma exporters began after Trump hinted at imposing "never-seen-before" tariffs on pharmaceutical imports (Thursday, US time).

While marginal tariffs may not cause much disruption, steep duties could hurt the profit margins of Indian drugmakers.

The United States is a key market for India’s pharmaceutical exports, with India supplying around 40 per cent of all generic drugs used in the US.

Indian pharmaceutical exports to the US are worth nearly $9 billion annually. Any sharp increase in tariffs could not only affect Indian exporters but may also have a direct impact on American consumers, according to a report by NDTV Profit on Friday.

Trump has introduced a new wave of tariffs targeting multiple sectors. These include a 25 per cent tariff on all imported cars and light-duty trucks, and a 10 per cent minimum tariff on other imported goods.

India has been hit with a compound reciprocal tariff rate of 27 per cent.

The government is reportedly assessing the situation closely and is working with exporters to understand the potential impact and explore ways to mitigate risks, the report mentioned.

The latest Trump statement has left Indian pharma firms worried, many of which rely heavily on the US market for business. The stocks of Indian pharmaceutical companies were trading significantly lower during the day.

Shares of Aurobindo Pharma, Laurus Labs, IPCA Laboratories, and Lupin fell by up to 8 per cent on the National Stock Exchange (NSE) in the intra-day trading.

In the previous trading session on April 3, shares of domestic pharmaceutical companies gained some relief, even as other sectors faced heavy selling pressure. This came after the White House excluded pharmaceutical products from the reciprocal tariffs.

(This report has been published as part of the auto-generated syndicate wire feed. Apart from the headline, no editing has been done in the copy by ABP Live.)

Top Headlines

STT, LTCG, STCG: What Stock Market Investors May Get In Budget 2027
STT, LTCG, STCG: What Stock Market Investors May Get In Budget 2027
Dalal Street Ends In Red As Sensex Falls Over 500 Points, Nifty Tests 25,200
Dalal Street Ends In Red As Sensex Falls Over 500 Points, Nifty Tests 25,200
Microsoft, Apple, NSA Outages Within A Week: Is America's Digital Infra Really That Fragile? Here's What Happened
Microsoft, Apple, NSA Outages Within A Week: Is America's Digital Infra Really That Fragile?
Delhi High Court: Corporate Guarantees To Subsidiaries Attract GST, But 1% Valuation Is Not A Mandatory Floor
Delhi High Court: Corporate Guarantees To Subsidiaries Attract GST, But 1% Valuation Is Not A Mandatory Floor

Videos

Yogi Address: CM Highlights UP’s Law-and-Order Transformation
Book Controversy: Shiv Sena Shinde Faction Demands Ban on Sonia Gandhi’s Book
NEET Paper Leak: Delhi Court Frames Charges Against All 14 Accused
Mathura Mission: Dhirendra Krishna Shastri Announces November 21 Visit for Krishna Temple Pledge
Court Action: Rouse Avenue Court Seeks Action-Taken Report in Sonia Gandhi Voter List Case!

Photo Gallery

25°C
New Delhi
Rain: 100mm
Humidity: 97%
Wind: WNW 47km/h
See Today's Weather
powered by
Accu Weather
Embed widget